Algomedix is a leader in the development of novel Transient Receptor Potential (TRP) therapeutics to treat serious medical needs including chronic and acute pain as well as chronic kidney disease.
The company has significant expertise in TRP research and currently has therapeutic candidates in development that hold potential to overcome limitations of current treatment approaches.
This includes a novel non-opioid, non-addictive TRPA1 antagonist for the treatment of pain. This new class of pain therapeutics holds potential to overcome the significant shortcomings of opioid drugs, which have significant abuse liability and addiction concerns, and non-steroidal anti-inflammatory drugs (NSAIDs) which have significant safety and tolerability limitations. With millions of Americans suffering from chronic and acute pain, new treatment alternatives are urgently needed.
The company is also advancing a novel TRPC6 therapeutic for the treatment of chronic kidney disease.
Algomedix is a private, emerging biopharmaceutical company headquartered in Mill Creek, Wash.